Mounjaro solution for injection 7.5 mg/0.6 mL is indicated for adults with type 2 diabetes to control blood sugar (glucose) levels.
Mounjaro®
Injectable solution 7.5 mg/0.6 mL, 4-dose prefilled pen
Composition:
7.5 mg/0.6 mL multidose prefilled pen
Mounjaro (Tirzepatide) is a prescription medication for adults with type 2 diabetes, used to control blood sugar (glucose) levels.
The medication is also indicated for the treatment of adults with obesity or overweight (BMI ≥ 27 kg/m²) who have weight-related health conditions, such as:
Prediabetes
Type 2 diabetes
Hypertension
Dyslipidemia
Mechanism of Action:
Tirzepatide is a dual GIP and GLP-1 receptor agonist, belonging to a new class of medications called incretin mimetics.
Each pen contains four fixed doses, providing a one-month supply (one injection per week).
Reduces blood sugar levels
Helps the pancreas produce more insulin
Reduces glucose production in the liver
Slows gastric emptying
Prolongs the feeling of fullness
Can reduce food intake
These effects help maintain stable blood glucose levels throughout the day.
Most common side effects:
Nausea
Diarrhea
Decreased appetite
Vomiting
Constipation
Dyspepsia
Abdominal pain
Seek immediate medical attention if you experience:
Signs of an allergic reaction: hives, difficulty breathing
Contact your doctor for:
Severe stomach issues
Gallbladder problems with symptoms
Stomach pain after eating
Kidney problems with little or no urine
Swelling of the ankles
Fatigue or coughing
Contraindications:
Personal or family history of medullary thyroid carcinoma (MTC)
Multiple endocrine neoplasia type 2 (MEN 2)
Allergy to Tirzepatide
Precautions:
Inform your doctor if you have pancreas or kidney problems
Notify your doctor if you are pregnant or planning pregnancy
May reduce effectiveness of birth control pills
Inject once weekly into the abdomen, thigh, or upper arm
Always try to inject on the same day each week
Each pen contains 4 fixed doses, enough for one month
For adults with type 2 diabetes:
Starting dose: 2.5 mg subcutaneous, once weekly
After 4 weeks: increase to 5 mg subcutaneous, once weekly
If additional glycemic control is needed: increase by 2.5 mg at intervals of at least 4 weeks
Maximum dose: 15 mg subcutaneous, once weekly
Do not change the dose without your doctor’s instructions
Unused prefilled pen:
Store in a refrigerator at 2°C–8°C
Do not freeze
Use before the expiration date
After first use:
Can be stored at room temperature (≤ 30°C) for up to 30 days
Keep away from heat and direct sunlight
Discard after 30 days, even if medication remains
Important Note:
Always use Mounjaro under the supervision of a healthcare professional
